T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity

被引:1
|
作者
Canel, Marta [1 ]
Taggart, David [1 ]
Sims, Andrew H. [2 ]
Lonergan, David W. [1 ]
Waizenegger, Irene C. [3 ]
Serrels, Alan [1 ]
机构
[1] Univ Edinburgh, Queens Med Res Inst, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland
[2] Univ Edinburgh, Inst Genet & Mol Med, MRC, Canc Res UK,Edinburgh Ctr, Edinburgh, Midlothian, Scotland
[3] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
来源
ELIFE | 2020年 / 9卷
关键词
FOCAL-ADHESION KINASE; NEXT-GENERATION; PD-1; BLOCKADE; TUMOR-CELLS; TGF-BETA; CANCER; CD80; IMMUNOTHERAPY; COSTIMULATION; PROMOTES;
D O I
10.7554/elife.48092
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Focal Adhesion Kinase (FAK) inhibitors are currently undergoing clinical testing in combination with anti-PD-1 immune checkpoint inhibitors. However, which patients are most likely to benefit from FAK inhibitors, and what the optimal FAK/immunotherapy combinations are, is currently unknown. We identify that cancer cell expression of the T-cell co-stimulatory ligand CD80 sensitizes murine tumors to a FAK inhibitor and show that CD80 is expressed by human cancer cells originating from both solid epithelial cancers and some hematological malignancies in which FAK inhibitors have not been tested clinically. In the absence of CD80, we identify that targeting alternative T-cell co-stimulatory receptors, in particular OX-40 and 4-1BB in combination with FAK, can drive enhanced anti-tumor immunity and even complete regression of murine tumors. Our findings provide rationale supporting the clinical development of FAK inhibitors in combination with patient selection based on cancer cell CD80 expression, and alternatively with therapies targeting T-cell co-stimulatory pathways.
引用
收藏
页数:23
相关论文
共 50 条
  • [41] MM-401, a novel anti-TNFR2 antibody that induces T cell co-stimulation, robust anti-tumor activity and immune memory
    Richards, Jennifer
    Wong, Christina
    Koshkaryev, Alexander
    Fulton, Ross
    Camblin, Adam
    Sampson, James
    Luus, Lia
    Suchy, James
    Grabow, Stephanie
    Kurella, Vinodh
    Kumar, Sandeep
    Lulo, James
    Qiu, James
    Jiao, Yang
    Xu, Lihui
    Paragas, Violette
    Razlog, Maja
    Muda, Marco
    Tam, Eric
    Raue, Andreas
    Drummond, Daryl
    CANCER RESEARCH, 2019, 79 (13)
  • [42] LIGHT (TNFSF14) CO-STIMULATION ENHANCES MYELOID CELL ACTIVATION AND ANTI-TUMOR IMMUNITY IN THE SETTING OF PD-1 AND TIGIT CHECKPOINT BLOCKADE
    Fromm, George
    Yoo, Kyung Jin
    Johannes, Kellsey
    Shuptrine, Casey
    Opheim, Zach
    Patel, Arpita
    Andreasen, Haley
    Miriyala, Jaya
    De Silva, Suresh
    Schreiber, Taylor
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A615 - A615
  • [43] Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity
    Waugh, Katherine A.
    Leach, Sonia M.
    Slansky, Jill E.
    VACCINES, 2015, 3 (03) : 771 - 802
  • [44] Co-stimulation and plaque-antigen-specific T-cell responses in atherosclerosis
    Buono, C
    Lichtman, AH
    TRENDS IN CARDIOVASCULAR MEDICINE, 2004, 14 (04) : 166 - 172
  • [45] Non-conventional mechanisms of T-cell co-stimulation by endothelial cells
    Orosz, CG
    Pidwell, D
    Adams, PW
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) : 733 - 736
  • [46] Modulation of T-Cell Co-Stimulation in Rheumatoid Arthritis Clinical Experience with Abatacept
    Lagana, Bruno
    Vinciguerra, Marta
    D'Amelio, Raffaele
    CLINICAL DRUG INVESTIGATION, 2009, 29 (03) : 185 - 202
  • [47] Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation
    Bleakley, Marie
    Turtle, Cameron J.
    Riddell, Stanley R.
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (04) : 409 - 425
  • [48] CD28 co-stimulation in T-cell homeostasis: a recent perspective
    Beyersdorf, Niklas
    Kerkau, Thomas
    Huenig, Thomas
    IMMUNOTARGETS AND THERAPY, 2015, 4 : 111 - 122
  • [49] The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept
    Snanoudj, Renaud
    Frangie, Carlos
    Deroure, Benjamin
    Francois, Helene
    Creput, Caroline
    Beaudreuil, Severine
    Durrbach, Antoine
    Charpentier, Bernard
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (03): : 203 - 213
  • [50] Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis
    Sibilia, J.
    Westhovens, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (05) : S46 - S56